MD, PhD - Urology resident @UZLeuven @azsintjanbrugge #ProstateCancer
Joined August 2018
- Tweets82
- Following312
- Followers301
- Likes1.3K
Pinned Tweet
Very proud to present the ARNEO study published in @EUplatinum!!
In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone!
@joniau
A thread🧵👇:
authors.elsevier.com/c/1fow7…
Gaëtan Devos retweeted
Read all about metformin and prostate cancer here: euoncology.europeanurology.c… @devos_gaetan
Gaëtan Devos retweeted
ADT in both arms was deliberate: isolates apalutamide's contribution AND enables the pathological co-primary endpoint (pCR/MRD) — impossible in a surgery-alone design. Deep pathological response predicts BCR-FS and MFS. A scientific necessity, not a flaw. @devos_gaetan @TheGiesen
Gaëtan Devos retweeted
Pleased to share that our editorial has been published in European Urology Oncology. We reviewed the randomized evidence on metformin in prostate cancer and found no consistent improvement in meaningful oncologic outcomes across disease stages. The recent SAKK 08/14 trial highlights how future progress may depend less on empirical drug repurposing and more on biomarker-driven strategies, with PTEN as a potential lead. @devos_gaetan @EurUrolOncol
sciencedirect.com/science/ar…
Gaëtan Devos retweeted
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer by Gaëtan Devos et al
Full article: europeanurology.com/article/…
Gaëtan Devos retweeted
Congratulations again to #ARNEO study @devos_gaetan @joniau @TheGiesen
▶️MRD doesn't predict BCR
▶️We will need to wait for a possible significant impact on MFS with longer FU
▶️ypT stage correlates with outcomes
👉 Did downstaging after neoadjuvant treatment correlate with BCR?
Today we presented the 3 year oncological outcomes of the ARNEO trial:
- Patients treated with 3 mo neoadjuvant ADT + Apalutamide have tendency towards improved BCR free and metastasis free survival.
- pT2 disease associated with less biochemical recurrence.
@joniau @TheGiesen
Today we presented the 3 year oncological outcomes of the ARNEO trial:
- Patients treated with 3 mo neoadjuvant ADT + Apalutamide have tendency towards improved BCR free and metastasis free survival.
- pT2 disease associated with less biochemical recurrence.
@joniau @TheGiesen
Three-year oncological outcomes of the randomized phase II trial #ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for HR #ProstateCancer. Presented by @devos_gaetan @UZLeuven. #EAU24 written coverage > bit.ly/3TNxJxI @RKSayyid
Gaëtan Devos retweeted
The last day of the #BAU2023 congress is being kicked off with an interesting #ProstateCancer case, presented by @devos_gaetan and moderated by @joniau @vandamme_jvd! Please find the programme on our website 👇 @sb_uro @Uroweb @esru_be bau.be/programme/
Nice work by @KarelDavid_ !
Three months of neoadjuvant ADT in high-risk PCa patients results in early bone loss. These findings underscore the importance for bone health prevention in men treated with ADT . @Uroweb @UZLeuven
Happy to see our work highlighted during this #Movember month! Don't forget the impact of #androgendeprivation on #bone in #prostatecancer patients! bit.ly/3G3LKkd
Great collaboration with our urology department @devos_gaetan @WoutDevlies @joniau
👇👇👇
Gaëtan Devos retweeted
Great presentation of #ARNEO results by @joniau #UroOnco23 Neoadjuvant treatment apa/ADT vs ADT prior to RP in #prostatecancer: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR
Gaëtan Devos retweeted
Proud to present our article in @EurUrolOncol: Predictors of recurrence after MDT in oligometastatic prostateCa. Free version below. authors.elsevier.com/a/1ghXV…
Thanks to @joniau @GertMeerleer @CharlienBerghen @J_Kuijk @Eduardrssl @devos_gaetan @VdBroeckThomas @ThomasVdB9
Gaëtan Devos retweeted
Congratulations to @devos_gaetan for defending his PhD last week🎓👏!
Very proud promotor of @devos_gaetan, who defended his PhD last Friday. Great conclusions and a new adagio: “Eat, sleep, MDT, repeat”. Co-promotors @GertMeerleer & @EveraertsW. Jury @Albert0Briganti, @BertrandTOMBAL, @PieterUvin, prof Claessens and prof Dumez
Gaëtan Devos retweeted
Very proud promotor of @devos_gaetan, who defended his PhD last Friday. Great conclusions and a new adagio: “Eat, sleep, MDT, repeat”. Co-promotors @GertMeerleer & @EveraertsW. Jury @Albert0Briganti, @BertrandTOMBAL, @PieterUvin, prof Claessens and prof Dumez
Gaëtan Devos retweeted
Excellent dinner after impressive PhD thesis by Gaetan Devos. High-risk prostate cancer and clear evidence in metastasis-directed therapy. Happy to be part of this team. #respect #prostatecancer #SBRT #arneo #oligo @joniau @heinvanpoppel @BertrandTOMBAL
Gaëtan Devos retweeted
Impressive PhD defense yesterday from @devos_gaetan exploring high-risk and oligometastatic prostate cancer, with rightly proud promotors @joniau @EveraertsW @GertMeerleer. Great honour to be in the jury with @Albert0Briganti, @BertrandTOMBAL, Prof Claessens and Prof Durmez. – at Bruges, Belgium
Gaëtan Devos retweeted
💥 Congratulations to dr. @devos_gaetan for completing his PhD. with an excellent public defense @KU_Leuven
Gaëtan Devos retweeted
Neoadjuvant degarelix plus apalutamide results ina more favorable pathological outcome when compared with degarelix alone before #radicalprostatectomy.
Read more 👇
prostate.uroonco.uroweb.org/…
@devos_gaetan @joniau @yraskin @HendrikPoppel @GertMeerleer @roodvdb
#prostatecancer
Gaëtan Devos retweeted
Great job¡¡¡ Congrats to the UH Leuven...steps to a new therapeutic scenario in HR PCa...@joniau @devos_gaetan @GertMeerleer @EveraertsW @heinvanpoppel Lorenzo Tosco,Carl Van Haute et al
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
buff.ly/3dMB7rB
@devos_gaetan @joniau @HendrikPoppel @GertMeerleer
Gaëtan Devos retweeted
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
buff.ly/3dMB7rB
@devos_gaetan @joniau @HendrikPoppel @GertMeerleer
